The Biden administration this morning formally announced plans to rescind the controversial Trump administration final rule requiring community health centers to pass along all 340B drug discount savings on insulin and injectable epinephrine to low-income patients, as a condition for keeping their federal health center program grants.
The Health Resources and Services Administration (HRSA) posted the rescission proposal for public inspection on the Federal Register website. The actual proposed rule to do away with requirement will be published tomorrow. There will be a 30-day public comment period. Comments will be due on or before July 16.
The Biden administration this morning formally announced plans to rescind the controversial Trump administration final rule requiring community health centers to pass along all 340B drug discount savings on insulin and injectable epinephrine to low-income patients, as a condition for keeping their federal health center program grants.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, take advantage of our lowest-ever discount opportunity which we have extended through June 21: 25% off our regular subscription rates. Subscribe now using coupon code INVESTIGATE25 at checkout.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
